Skip to main content
CELC
NASDAQ Life Sciences

FDA Approves Celcuity's Gedatolisib for Advanced Breast Cancer

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
10
Price
$111.66
Mkt Cap
$5.445B
52W Low
$13.365
52W High
$151.02
52W Position info
735% above low
Off High info
26% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CELC has more than doubled off its 52-week low of $13.365.

Summary

The FDA approved Celcuity's gedatolisib in combination with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. This is the first regulatory approval for the company, transforming it from a clinical-stage to a commercial-stage biotech. The approval comes three days ahead of the July 17 PDUFA date, removing the key binary risk that has dominated the stock. With a $5.4 billion market cap, the approval validates the Phase 3 VIKTORIA-1 data and opens a multi-billion-dollar market opportunity. The recent $575 million convertible note offering provides ample capital for the commercial launch. Next catalyst: initial sales figures and launch metrics in the coming quarters.

At the time of this announcement, CELC was trading at $111.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.37 to $151.02. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $61.32 info
Change: -$5.00 (-8%) info
Market Cap: $3.011B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $61.32 info
Change: -$2.72 (-4%) info
Market Cap: $3.011B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $61.32 info
Change: -$2.72 (-4%) info
Market Cap: $3.011B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $61.32 info
Change: -$2.72 (-4%) info
Market Cap: $3.011B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $61.32 info
Change: -$17.68 (-22%) info
Market Cap: $3.011B info